HARRISBURG – State Rep. Jim Struzzi (R-Indiana) today announced that the House Health Committee has passed two resolutions he authored. House Resolution 459
would request guidelines for the commercial sale of CBD products from the Food and Drug Administration (FDA). House Resolution 460 would request guidance and appropriate protocol from the FDA for the safe use of Kratom.
“The affects of these products are still relatively unknown. Without oversight from the FDA, there is a lack of consistency in the market. This leads to retailers not being fully knowledgeable about the products they sell, and consumers not being fully knowledgeable about the products they purchase,” said Struzzi. “My resolutions would go a long way in providing clear guidelines for the sale and use of these products so retailers and consumers know they are being safe and responsible.”
The sale of CBD became legal in Pennsylvania though the 2018 Federal Farm Bill, but lacks clear guidance from the FDA regarding its sale and use. Kratom is not a currently scheduled drug on FDA list of controlled substances.
Representative Jim Struzzi
62nd Legislative District
Pennsylvania House of Representatives